Please login to the form below
trastuzumab
This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
Keytruda is still approved in combination with Roche’s Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive
Latest news
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
Datopotamab deruxtecan is the second ADC in development as part of AZ and Daiichi’s partnership, the first being Enhertu (trastuzumab deruxtecan).
-
FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
The approval is based on data from the ongoing phase 3 KEYNOTE-811 trial, evaluating the Keytruda (pembrolizumab), Herceptin (trastuzumab) and chemotherapy combination in patients with HER2-positive advanced gastric or
-
UK approval for Seagen’s oral HER2 inhibitor Tukysa
In 2019, Seagen announced that it had initiated another trial of Tukysa – the HER2CLIMB-02 study – that will compare Tukysa to placebo in combination with Kadcyla (ado-trastuzumab emtansine) in
-
Roche’s diagnostic business sales offer a bright spot in Q4
treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
-
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination
The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, has been authorised for use for the treatment of early and metastatic HER2-positive breast cancer.
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
UK approval for Seagen’s oral HER2 inhibitor Tukysa
Roche’s diagnostic business sales offer a bright spot in Q4
More from news
Approximately 14 fully matching, plus 173 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
The rise of the monoclonal antibody. Trastuzumab was the first monoclonal antibody tested in clinical trials, designed to inhibit human epidermal growth factor receptor 2 (HER2) which, when activated, promotes breast ... Trastuzumab successfully reduced
-
Cortellis Drugs to Watch in 2020 report
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our
-
2016: The year when deal-makers took stock?
Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .
-
Deal Watch October 2016
Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
Surviving cancer: a new era for patients
Cortellis Drugs to Watch in 2020 report
20 for 2020 – Five pharma companies to watch
2016: The year when deal-makers took stock?
Deal Watch October 2016
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
AVEO's financial head joins ImmunoGen
cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.
AVEO's financial head joins ImmunoGen
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- David Hunt launches independent agency The Considered
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
